ABSTRACT
BACKGROUND: The introduction of nucleic acid amplification technology (NAT) for screening pooled or individual donations remarkably improved the safety of blood products. The size of mini-pooled NAT is considered critical for identification of HIV-1 infected donors during preseroconversion phase of infection. We describe a case of HIV-1 infection in a serologically negative repeat blood donor identified by 16 minipool (MP) NAT. MATERIALS AND METHODS: The donation was tested by Roche Cobas AmpliScreen HIV-1 Test with manual extraction (MultiPrep Specimen Processing Procedure). The sensitivity of different MP sizes was observed. Serial samples of infected donor were examined with different third and fourth generation HIV-1 serological assays. RESULTS: In the index donation viral load was 515 copies/ml corresponding to about 50 IU when diluted in 16 MP. Abbott third and fourth generation EIA tests detected the seroconversion four days later the index donation. CONCLUSION: The report emphasizes the relevance of a very small size of MP to really reduce the window serologic phase of current EIA test by HIV-1 NAT test.
Subject(s)
Blood Donors , HIV Seropositivity/blood , HIV-1 , RNA, Viral/blood , Reverse Transcriptase Polymerase Chain Reaction , Viral Load , Adult , Humans , Male , Reverse Transcriptase Polymerase Chain Reaction/methods , Viral Load/methodsABSTRACT
No disponible
Subject(s)
Humans , Larva/pathogenicity , Hypersensitivity/etiology , Immunoblotting/methods , Allergens/isolation & purification , Allergens , Skin Tests/methodsABSTRACT
No disponible
Subject(s)
Adult , Aged , Female , Male , Humans , Angioedema/drug therapy , Melkersson-Rosenthal Syndrome/diagnosis , Methylprednisolone/therapeutic use , Pheniramine/therapeutic use , Diagnosis, Differential , Minocycline/therapeutic use , Skin TestsSubject(s)
Drug Eruptions/etiology , Spironolactone/adverse effects , Administration, Oral , Allergens/adverse effects , Dose-Response Relationship, Drug , Drug Eruptions/diagnosis , Female , Follow-Up Studies , Humans , Liver Cirrhosis/drug therapy , Middle Aged , Patch Tests , Risk Assessment , Sensitivity and Specificity , Spironolactone/administration & dosageABSTRACT
A 72-year-old woman presented with generalized urticaria after receiving an injection of aztreonam. After successive in vitro and in vivo studies, allergy to aztreonam with a good tolerance of the other beta-lactams was diagnosed.
Subject(s)
Aztreonam/adverse effects , Drug Eruptions/etiology , Urticaria/chemically induced , Aged , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/immunology , Aztreonam/chemistry , Aztreonam/immunology , Cross Reactions , Drug Eruptions/diagnosis , Female , Humans , Skin Tests , Structure-Activity RelationshipABSTRACT
A study has been performed of the prevalence of allergic pathology in the geriatric population attending our department during a period of one year, showing that this type of clinical problem affects 10.4% of our patients 60 years or older. In spite of such considerable prevalence, immunotherapy is not normally used with this age group. This paper describes the results of hyposensitization in 22 of these patients, diagnosed as having extrinsic allergic illness by means of clinical, functional and analytical parameters. We found a significant decrease in cutaneous sensitivity, bronchial hyperreactivity and specific IgE in the patients treated with immunotherapy, as well as a subjective clinical improvement. We feel that immunotherapy can be very effective for the geriatric population, offering the advantages of not requiring self-administration by the older patients and avoiding the secondary effects already described with other kinds of antiallergic medications.
Subject(s)
Conjunctivitis, Allergic/therapy , Desensitization, Immunologic , Respiratory Hypersensitivity/therapy , Aged , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/epidemiology , Conjunctivitis, Allergic/immunology , Cross-Sectional Studies , Desensitization, Immunologic/adverse effects , Female , Humans , Immunoglobulin E/blood , Male , Middle Aged , Respiratory Hypersensitivity/diagnosis , Respiratory Hypersensitivity/epidemiology , Respiratory Hypersensitivity/immunology , Safety , Treatment OutcomeABSTRACT
Hepatitis C virus (HCV) has been demonstrated to be the main cause of non-A, non-B hepatitis and the emergent infectious illness in dialysis units. At present, the anti-HCV 100 ELISA and an immunoblot assay in which 2 new antigens are included, are available. We have tested 110 patients on chronic dialysis with anti-C100 ELISA. Twenty-seven of them were anti-HCV positive. We tested the 27 anti-HCV-positive and 7 anti-HCV-negative patients with the RIBA 4 assay. The results were similar with both test.
Subject(s)
Hepacivirus/immunology , Hepatitis Antibodies/blood , Enzyme-Linked Immunosorbent Assay/methods , Evaluation Studies as Topic , Hepatitis C Antibodies , Humans , Immunoblotting/methods , Renal Dialysis/adverse effectsABSTRACT
The prevalence of antibodies to hepatitis C virus (HCVAb) was investigated in 52 unselected patients with mixed cryoglobulinemia and in 84 patients with other systemic immunologic diseases. HCVAb were detected by an enzyme-linked immunosorbent assay, and their specificity was evaluated by a recombinant-based immunoblot assay. The presence of HBV-related markers was investigated in the same samples. HCVAb were found in 54% of mixed cryoglobulinemia patients, and the finding was confirmed by recombinant-based immunoblot assay in all cases. HCVAb and/or HBV markers were present in 70% of the patients. HCVAb seropositivity was significantly more frequent in mixed cryoglobulinemia patients with biopsy-proven liver involvement (P less than 0.01) and with increased serum transaminase levels (P less than 0.01). HCVAb were virtually absent in control patients with other immunologic diseases. These results support the notion that viral agents, i.e., HCV and possibly HBV, have a role in the pathogenesis of mixed cryoglobulinemia patients.
Subject(s)
Cryoglobulinemia/immunology , Hepacivirus/immunology , Hepatitis Antibodies/blood , Adult , Aged , Aged, 80 and over , Biopsy , Cryoglobulinemia/epidemiology , Cryoglobulinemia/etiology , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis Antibodies/immunology , Hepatitis Antibodies/physiology , Humans , Immunoblotting , Liver/pathology , Male , Middle Aged , PrevalenceABSTRACT
The prevalence of antibodies against hepatitis C virus (anti-HCV) in an unselected series of 45 mixed cryoglobulinemia patients was assessed by an enzyme linked immunosorbent assay (Chiron ELISA HCV, Second Generation). The anti-HCV specificity was evaluated by a recombinant based immunoblot assay (Chiron RIBA HCV, Second Generation Assay). HBV-related markers and HIVAb were detected in the same samples. The prevalence of anti-HCV observed in mixed cryoglobulinemia was compared with 80 patients with other immunological systemic diseases. Anti-HCV were found in 91% of mixed cryoglobulinemia patients, and confirmed by RIBA in all cases; on the other hand, anti-HCV were practically absent in other control diseases. HBV markers were recorded in 49% of mixed cryoglobulinemia subjects; while HIVAb were constantly absent. These data give us new insights into the etiopathogenesis of mixed cryoglobulinemia.
Subject(s)
Cryoglobulinemia/immunology , Hepacivirus/immunology , Hepatitis Antibodies/analysis , Adult , Aged , Aged, 80 and over , Antibody Specificity , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis C Antibodies , Humans , Immunoblotting , Male , Middle AgedABSTRACT
The prevalence of hepatitis C virus (HCV) RNA and of antibodies to HCV in an unselected series of 42 mixed cryoglobulinemia patients was investigated in this study. HCV RNA was detected by the polymerase chain reaction technique, and HCV antibodies by two enzyme-linked immunosorbent assays (Chiron ELISA HCV, Second Generation, Emeryville CA, USA; Wellcome Diagnostic, England). HCV RNA was found in 86% of the mixed cryoglobulinemia patients. Using either the Chiron ELISA or the Wellcome ELISA, HCV antibodies were present in 90% of the same samples; anti-HCVAb seropositivity was confirmed in all cases by immunoblot assay (Chiron RIBA HCV, Second Generation Assay). A striking correlation between HCV RNA and anti-HCV antibody seropositivities was recorded. HCV RNA in mixed cryoglobulinemia patients was not correlated with the presence or absence of biopsy-proven liver involvement. These results suggest that the association between HCV and mixed cryoglobulinemia is not fortuitous, and therefore that HCV may have an etiopathogenetic role in this disorder.
